title: Bleomycin stimulates lung fibroblast and epithelial cell lines to release eosinophil chemotactic activity.
abstract: The presence of eosinophils in the lungs of patients with pulmonary fibrosis correlates with poor prognosis or resistance to therapy. Furthermore, eosinophils localize to areas undergoing active fibrosis. It was hypothesized that a human lung fibroblast (HFL-1) and a human lung epithelial cell line (BEAS-2B) might release eosinophil chemotactic activity (ECA) in response to bleomycin, a chemotherapeutic agent associated with pulmonary fibrosis. HFL-1 and BEAS-2B cells were cultured in the presence of bleomycin and their supernatant fluids evaluated for ECA by means of a Boyden chamber method. HFL-1 and BEAS-2B cells released ECA in a dose- and time-dependent manner in response to bleomycin, and partial characterization revealed that the ECA was heterogeneous. ECA release from HFL-1 and BEAS-2B cells was significantly reduced by a leukotriene B4 (LTB4) receptor antagonist and an antibody directed against granulocyte-macrophage colony-stimulating factor. HFL-1 cells released LTB4, eotaxin, and GM-CSF constitutively, and BEAS-2B cells released LTB4, eotaxin, regulated on activation, normal T-cell expressed and presumably secreted, and GM-CSF constitutively. In both cases, the release of GM-CSF was significantly increased in response to bleomycin. These data suggest that lung fibroblasts and epithelial cells may modulate eosinophil recruitment into the lung in bleomycin-induced pulmonary fibrosis.
authors.affiliation: Arizona Veterans Health Care System, and Dept of Medicine, University of Arizona, Tucson, USA.
authors.forename: E
authors.initials: E
authors.lastname: Sato
authors.forename: S
authors.initials: S
authors.lastname: Koyama
authors.forename: R A
authors.initials: RA
authors.lastname: Robbins
mesh_terms: D000906:Antibodies / Q000494:pharmacology; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001761:Bleomycin / Q000494:pharmacology*; D002460:Cell Line; D054413:Chemokine CCL11; D019742:Chemokines, CC; D002631:Chemotactic Factors, Eosinophil / Q000037:antagonists & inhibitors / Q000378:metabolism*; D016207:Cytokines / Q000276:immunology / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004847:Epithelial Cells / Q000378:metabolism; D005347:Fibroblasts / Q000378:metabolism; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000276:immunology / Q000378:metabolism; D006801:Humans; D015848:Interleukin-5 / Q000276:immunology / Q000378:metabolism; D007975:Leukotriene B4 / Q000378:metabolism; D008168:Lung / Q000166:cytology / Q000378:metabolism*; D010666:Phenylpropionates / Q000494:pharmacology; D018102:Receptors, Leukotriene B4 / Q000037:antagonists & inhibitors; D013997:Time Factors
chemical_list: D000906:Antibodies; D000964:Antimetabolites, Antineoplastic; C515456:CCL11 protein, human; D054413:Chemokine CCL11; D019742:Chemokines, CC; D002631:Chemotactic Factors, Eosinophil; D016207:Cytokines; D015848:Interleukin-5; D010666:Phenylpropionates; D018102:Receptors, Leukotriene B4; D001761:Bleomycin; C067523:ONO-LB 457; D007975:Leukotriene B4; D016178:Granulocyte-Macrophage Colony-Stimulating Factor